NasdaqGM:STIMMedical Equipment
Neuronetics (STIM) Stock Repriced After Margin Gains And EBITDA Breakeven
The market just put Neuronetics on a pedestal. The stock surged 47% today, capping a run that had already been strong over the past month, after a Q2 report that gave traders something more concrete to evaluate. The headline is margin and cash discipline. Gross margin stepped up into the low 50% range and adjusted earnings before interest, tax, depreciation and amortization flipped slightly positive as the company still reported a loss of US$3.4m.
For a historically loss making medical...